Considering the high heterogeneity of RA individuals may influence the expression of Cyr61, we then investigated the relationship between Cyr61 and disease activity in our validation cohort based on a randomized and controlled clinical trial (ClinicalTrials.gov identifier: NCT02320630). Here, CCN1 is linked to rheumatoid arthritis.